Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
501-520 of 604 trials

Alcohol Use Disorder: Psilocybin Treatment

We are studying if a single dose of psilocybin can help reduce heavy drinking in people with alcohol use disorder. This trial compares the effects of psilocybin to a placebo over 12 weeks.

Alcohol Use Disorder>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Cardiovascular Risk: Allopurinol Study

We are investigating if allopurinol can lower cardiovascular risks in patients with high risk, including those experiencing long-COVID. This study focuses on individuals over 60 years old as well.

Heart FailureHypertensionAtrial Fibrillation>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyEndocrinologyInternal Medicine

Surgery and Immune Response: Low-Dose Interferon-alfa2a Study

We are investigating whether low-dose Interferon-alfa2a can improve immune function and recovery in patients undergoing surgery. This study looks at immune cell changes and recovery quality compared to a placebo.

Colon Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Managing High Potassium: Lokelma for Chronic Kidney Disease

We are studying whether Sodium Zirconium Cyclosilicate (Lokelma) can help lower potassium levels in patients with chronic kidney disease. This trial compares it to standard treatments to find the best approach.

High Potassium Levels in Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Hidradenitis Suppurativa: Ruxolitinib Cream Study

We are evaluating a new cream for people with hidradenitis suppurativa to see if it helps reduce symptoms and is safe to use. This study aims to find out how effective the cream is compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementDermatology

Ataxia-Telangiectasia: N-Acetyl-L-Leucine Study

We are studying whether N-Acetyl-L-Leucine can improve symptoms and quality of life for people with Ataxia-Telangiectasia. The trial will also assess the safety of this treatment.

Ataxia Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Dexamethasone for Severe Burns

We are studying whether early treatment with dexamethasone can help reduce serious complications and death in patients with severe burns. This trial will also look at its effects on infections and recovery times.

Severe Burns3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Post-COVID-19 Syndrome: Vericiguat Study

We are investigating whether Vericiguat can improve physical function and reduce fatigue in individuals with post-COVID-19 syndrome compared to a placebo. This study aims to assess various aspects of health and safety related to the treatment.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

COVID-19: Ibuzatrelvir Study for High-Risk Patients

We are investigating whether ibuzatrelvir can help reduce symptoms and prevent severe illness in non-hospitalized adults and adolescents with COVID-19. This study compares the medication to a placebo to see how effective it is.

COVID-193-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Lower Limb Nonunion: NVD-003 Implant Study

We are testing a new 3D bone implant for adults with nonunion fractures in the lower limb. The study aims to evaluate its safety and effectiveness in promoting healing and improving quality of life.

Recalcitrant Lower Limb Nonunion1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and Traumatology

Moderate-to-Severe Asthma: PF-07275315 Study

We are investigating a new medication called PF-07275315 for adults with moderate-to-severe asthma. The study aims to see if it is more effective than a placebo in improving asthma control and quality of life.

Moderate-to-Severe Asthma6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyPulmonology

Nephrotic Syndrome: Ketoanalogues for Muscle Preservation

We are studying a new treatment to help prevent muscle loss in patients with nephrotic syndrome. This trial will assess its safety and how it may improve overall health and quality of life.

Protein-Energy Wasting in Nephrotic Syndrome>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Atherosclerosis: Psilocybin Therapy Study

We are exploring if psilocybin-assisted therapy can help reduce plaque buildup in patients with ischemic heart disease. This study will also look at safety and changes in plaque characteristics over time.

Stable Ischemic Heart DiseaseEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Autoimmune Uveitis: Probiotic Supplement Study

We are studying the effects of a probiotic on people with autoimmune uveitis to see if it improves vision and reduces inflammation. The trial will also check the safety of this treatment.

Autoimmune Uveitis1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOphthalmology

Non-Small Cell Lung Cancer: Sigvotatug Vedotin with Pembrolizumab

We are studying a new treatment combining sigvotatug vedotin with pembrolizumab for patients with advanced non-small cell lung cancer that has high PD-L1 levels. The goal is to see if this combination works better than pembrolizumab alone.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Chronic Migraine: CGRP Monoclonal Antibody and Botox Combination Therapy

We are investigating whether a combination of CGRP monoclonal antibodies and Botox can reduce the number of migraine days for adults with chronic migraines. This study compares the effects of this dual therapy to a single treatment with CGRP monoclonal antibodies.

Chronic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Prostate Cancer: Ebastine with Docetaxel or Cabazitaxel

We are studying a new treatment combining ebastine with either docetaxel or cabazitaxel for men with metastatic castration-resistant prostate cancer. The goal is to evaluate how this combination affects cancer markers and PSA levels.

Hormone-Refractory Prostate Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Schizophrenia: Cariprazine for Cognitive Function

We are studying how cariprazine affects cognitive functioning in patients with schizophrenia who need changes to their current treatment. The trial will also look at overall quality of life and any side effects.

Acute Schizophrenia6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPsychiatry

Moderate Atopic Dermatitis: Ruxolitinib Cream for Kids

We are studying a new cream for children and adolescents aged 6 to under 18 with moderate atopic dermatitis who haven't had success with other treatments. The trial will assess how well it works and its safety.

Atopic Dermatitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Alcohol Dependence: CBD and Naltrexone Study

We are investigating whether adding Cannabidiol to Naltrexone helps reduce alcohol cravings in people with alcohol dependence. The study also looks at its effects on mood, anxiety, and overall quality of life.

Alcohol Dependence>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry